---
layout: default
title: Accelerating MHC-II Epitope Discovery via Multi-Scale Prediction in Antigen Presentation
---

# Accelerating MHC-II Epitope Discovery via Multi-Scale Prediction in Antigen Presentation

**arXiv**: [2512.14011v1](https://arxiv.org/abs/2512.14011) | [PDF](https://arxiv.org/pdf/2512.14011.pdf)

**ä½œè€…**: Yue Wan, Jiayi Yuan, Zhiwei Feng, Xiaowei Jia

**åˆ†ç±»**: cs.LG, q-bio.QM

**å‘å¸ƒæ—¥æœŸ**: 2025-12-16

---

## ðŸ’¡ ä¸€å¥è¯è¦ç‚¹

**æå‡ºå¤šå°ºåº¦é¢„æµ‹æ¡†æž¶ï¼ŒåŠ é€ŸMHC-IIæŠ—åŽŸè¡¨ä½å‘çŽ°ï¼ŒåŠ©åŠ›å…ç–«æ²»ç–—ã€‚**

ðŸŽ¯ **åŒ¹é…é¢†åŸŸ**: **ä¸–ç•Œæ¨¡åž‹ä¸Žé¢„æµ‹ (World Models)**

**å…³é”®è¯**: `MHC-II` `æŠ—åŽŸè¡¨ä½` `å…ç–«æ²»ç–—` `æœºå™¨å­¦ä¹ ` `å¤šå°ºåº¦é¢„æµ‹`

## ðŸ“‹ æ ¸å¿ƒè¦ç‚¹

1. MHC-IIæŠ—åŽŸè¡¨ä½ç ”ç©¶å› å…¶å¤æ‚æ€§é¢ä¸´æŒ‘æˆ˜ï¼ŒçŽ°æœ‰æ•°æ®é›†è§„æ¨¡å°ä¸”æ ‡å‡†åŒ–ç¨‹åº¦ä½Žã€‚
2. è®ºæ–‡æž„å»ºäº†å¤šå°ºåº¦é¢„æµ‹æ¡†æž¶ï¼Œä»Žè‚½ç»“åˆåˆ°æŠ—åŽŸå‘ˆé€’ï¼Œé€æ­¥æ•æ‰MHC-IIæŠ—åŽŸå‘ˆé€’çš„ç”Ÿç‰©å­¦è¿‡ç¨‹ã€‚
3. é€šè¿‡å¤šå°ºåº¦è¯„ä¼°ï¼Œè®ºæ–‡å¯¹çŽ°æœ‰æ¨¡åž‹è¿›è¡Œäº†åŸºå‡†æµ‹è¯•ï¼Œå¹¶åˆ†æžäº†å„ç§å»ºæ¨¡è®¾è®¡ï¼Œä¸ºæœªæ¥ç ”ç©¶å¥ å®šåŸºç¡€ã€‚

## ðŸ“ æ‘˜è¦ï¼ˆä¸­æ–‡ï¼‰

ä¸»è¦ç»„ç»‡ç›¸å®¹æ€§å¤åˆä½“IIç±»ï¼ˆMHC-IIï¼‰è›‹ç™½å‘ˆé€’çš„æŠ—åŽŸè¡¨ä½åœ¨å…ç–«æ²»ç–—ä¸­èµ·ç€è‡³å…³é‡è¦çš„ä½œç”¨ã€‚ç„¶è€Œï¼Œä¸Žè®¡ç®—å…ç–«æ²»ç–—ä¸­ç ”ç©¶æ›´ä¸ºå¹¿æ³›çš„MHC-Iç›¸æ¯”ï¼Œç”±äºŽå…¶å¤æ‚çš„ç»“åˆç‰¹å¼‚æ€§å’Œæ¨¡ç³Šçš„motifæ¨¡å¼ï¼ŒMHC-IIæŠ—åŽŸè¡¨ä½ç ”ç©¶é¢ä¸´ç€æ›´å¤§çš„æŒ‘æˆ˜ã€‚å› æ­¤ï¼ŒçŽ°æœ‰çš„MHC-IIç›¸äº’ä½œç”¨æ•°æ®é›†æ¯”MHC-Içš„æ•°æ®é›†æ›´å°ä¸”æ ‡å‡†åŒ–ç¨‹åº¦æ›´ä½Žã€‚ä¸ºäº†åº”å¯¹è¿™äº›æŒ‘æˆ˜ï¼Œæˆ‘ä»¬æå‡ºäº†ä¸€ä¸ªç²¾å¿ƒç­–åˆ’çš„æ•°æ®é›†ï¼Œè¯¥æ•°æ®é›†æºè‡ªå…ç–«è¡¨ä½æ•°æ®åº“ï¼ˆIEDBï¼‰å’Œå…¶ä»–å…¬å…±æ¥æºã€‚å®ƒä¸ä»…æ‰©å±•å’Œæ ‡å‡†åŒ–äº†çŽ°æœ‰çš„è‚½-MHC-IIæ•°æ®é›†ï¼Œè¿˜å¼•å…¥äº†ä¸€ä¸ªå…·æœ‰æ›´ä¸°å¯Œç”Ÿç‰©å­¦èƒŒæ™¯çš„æ–°åž‹æŠ—åŽŸ-MHC-IIæ•°æ®é›†ã€‚åˆ©ç”¨è¯¥æ•°æ®é›†ï¼Œæˆ‘ä»¬æž„å»ºäº†è‚½ç»“åˆã€è‚½å‘ˆé€’å’ŒæŠ—åŽŸå‘ˆé€’è¿™ä¸‰ä¸ªä¸»è¦çš„æœºå™¨å­¦ä¹ ï¼ˆMLï¼‰ä»»åŠ¡ï¼Œè¿™äº›ä»»åŠ¡é€æ­¥æ•æ‰äº†MHC-IIæŠ—åŽŸå‘ˆé€’é€”å¾„ä¸­æ›´å¹¿æ³›çš„ç”Ÿç‰©å­¦è¿‡ç¨‹ã€‚æˆ‘ä»¬è¿›ä¸€æ­¥é‡‡ç”¨å¤šå°ºåº¦è¯„ä¼°æ¡†æž¶æ¥è¯„ä¼°çŽ°æœ‰æ¨¡åž‹ï¼Œå¹¶å¯¹è¯¥é—®é¢˜çš„å„ç§å»ºæ¨¡è®¾è®¡è¿›è¡Œäº†å…¨é¢çš„æ¨¡å—åŒ–æ¡†æž¶åˆ†æžã€‚æ€»çš„æ¥è¯´ï¼Œè¿™é¡¹å·¥ä½œä¸ºæŽ¨è¿›è®¡ç®—å…ç–«æ²»ç–—æä¾›äº†ä¸€ä¸ªæœ‰ä»·å€¼çš„èµ„æºï¼Œä¸ºæœªæ¥åœ¨æœºå™¨å­¦ä¹ æŒ‡å¯¼ä¸‹çš„è¡¨ä½å‘çŽ°å’Œå…ç–«ååº”é¢„æµ‹å»ºæ¨¡çš„ç ”ç©¶å¥ å®šäº†åŸºç¡€ã€‚

## ðŸ”¬ æ–¹æ³•è¯¦è§£

**é—®é¢˜å®šä¹‰**ï¼šçŽ°æœ‰MHC-IIæŠ—åŽŸè¡¨ä½é¢„æµ‹æ–¹æ³•é¢ä¸´æ•°æ®é‡å°ã€æ•°æ®è´¨é‡å‚å·®ä¸é½çš„æŒ‘æˆ˜ï¼Œå¯¼è‡´æ¨¡åž‹æ³›åŒ–èƒ½åŠ›ä¸è¶³ã€‚åŒæ—¶ï¼ŒçŽ°æœ‰æ–¹æ³•é€šå¸¸åªå…³æ³¨è‚½æ®µä¸ŽMHC-IIçš„ç»“åˆï¼Œå¿½ç•¥äº†æŠ—åŽŸå¤„ç†å’Œå‘ˆé€’çš„å®Œæ•´ç”Ÿç‰©å­¦è¿‡ç¨‹ã€‚å› æ­¤ï¼Œéœ€è¦æ›´å…¨é¢ã€æ›´å‡†ç¡®çš„é¢„æµ‹æ¨¡åž‹ï¼Œä»¥åŠ é€ŸMHC-IIæŠ—åŽŸè¡¨ä½çš„å‘çŽ°ã€‚

**æ ¸å¿ƒæ€è·¯**ï¼šè®ºæ–‡çš„æ ¸å¿ƒæ€è·¯æ˜¯é€šè¿‡æž„å»ºä¸€ä¸ªå¤šå°ºåº¦é¢„æµ‹æ¡†æž¶ï¼Œå°†MHC-IIæŠ—åŽŸå‘ˆé€’è¿‡ç¨‹åˆ†è§£ä¸ºä¸‰ä¸ªé€æ­¥æ·±å…¥çš„ä»»åŠ¡ï¼šè‚½ç»“åˆã€è‚½å‘ˆé€’å’ŒæŠ—åŽŸå‘ˆé€’ã€‚è¿™ç§åˆ†è§£æ–¹å¼èƒ½å¤Ÿæ›´å¥½åœ°æ•æ‰ä¸åŒå°ºåº¦çš„ç”Ÿç‰©å­¦ä¿¡æ¯ï¼Œå¹¶åˆ©ç”¨æ›´ä¸°å¯Œçš„ç”Ÿç‰©å­¦èƒŒæ™¯çŸ¥è¯†æ¥æé«˜é¢„æµ‹å‡†ç¡®æ€§ã€‚

**æŠ€æœ¯æ¡†æž¶**ï¼šè¯¥æ¡†æž¶åŒ…å«æ•°æ®æ”¶é›†ä¸Žæ•´ç†ã€ä»»åŠ¡æž„å»ºã€æ¨¡åž‹è®­ç»ƒä¸Žè¯„ä¼°ä¸‰ä¸ªä¸»è¦é˜¶æ®µã€‚é¦–å…ˆï¼Œä»ŽIEDBç­‰å…¬å…±æ•°æ®åº“æ”¶é›†å¹¶æ•´ç†MHC-IIç›¸å…³æ•°æ®ï¼Œæž„å»ºé«˜è´¨é‡çš„æ•°æ®é›†ã€‚ç„¶åŽï¼ŒåŸºäºŽè¯¥æ•°æ®é›†æž„å»ºä¸‰ä¸ªæœºå™¨å­¦ä¹ ä»»åŠ¡ï¼šè‚½ç»“åˆé¢„æµ‹ã€è‚½å‘ˆé€’é¢„æµ‹å’ŒæŠ—åŽŸå‘ˆé€’é¢„æµ‹ã€‚æœ€åŽï¼Œé‡‡ç”¨å¤šå°ºåº¦è¯„ä¼°æ¡†æž¶å¯¹çŽ°æœ‰æ¨¡åž‹è¿›è¡ŒåŸºå‡†æµ‹è¯•ï¼Œå¹¶åˆ†æžä¸åŒå»ºæ¨¡è®¾è®¡å¯¹é¢„æµ‹æ€§èƒ½çš„å½±å“ã€‚

**å…³é”®åˆ›æ–°**ï¼šè®ºæ–‡çš„å…³é”®åˆ›æ–°åœ¨äºŽæå‡ºäº†ä¸€ä¸ªå¤šå°ºåº¦çš„é¢„æµ‹æ¡†æž¶ï¼Œè¯¥æ¡†æž¶èƒ½å¤Ÿä»Žè‚½ç»“åˆã€è‚½å‘ˆé€’å’ŒæŠ—åŽŸå‘ˆé€’ä¸‰ä¸ªä¸åŒå°ºåº¦ä¸Šå¯¹MHC-IIæŠ—åŽŸå‘ˆé€’è¿‡ç¨‹è¿›è¡Œå»ºæ¨¡ã€‚æ­¤å¤–ï¼Œè®ºæ–‡è¿˜æž„å»ºäº†ä¸€ä¸ªé«˜è´¨é‡çš„æŠ—åŽŸ-MHC-IIæ•°æ®é›†ï¼Œè¯¥æ•°æ®é›†åŒ…å«æ›´ä¸°å¯Œçš„ç”Ÿç‰©å­¦èƒŒæ™¯ä¿¡æ¯ï¼Œæœ‰åŠ©äºŽæé«˜æ¨¡åž‹çš„é¢„æµ‹å‡†ç¡®æ€§ã€‚ä¸ŽçŽ°æœ‰æ–¹æ³•ç›¸æ¯”ï¼Œè¯¥æ¡†æž¶èƒ½å¤Ÿæ›´å…¨é¢åœ°è€ƒè™‘MHC-IIæŠ—åŽŸå‘ˆé€’è¿‡ç¨‹ï¼Œä»Žè€Œæé«˜é¢„æµ‹çš„å‡†ç¡®æ€§å’Œå¯é æ€§ã€‚

**å…³é”®è®¾è®¡**ï¼šè®ºæ–‡ä¸­ï¼Œæ•°æ®é›†çš„æž„å»ºå’Œä»»åŠ¡çš„åˆ’åˆ†æ˜¯å…³é”®è®¾è®¡ã€‚æ•°æ®é›†çš„æž„å»ºéœ€è¦ä»”ç»†ç­›é€‰å’Œæ¸…æ´—æ•°æ®ï¼Œç¡®ä¿æ•°æ®çš„è´¨é‡å’Œä¸€è‡´æ€§ã€‚ä»»åŠ¡çš„åˆ’åˆ†éœ€è¦å……åˆ†è€ƒè™‘MHC-IIæŠ—åŽŸå‘ˆé€’çš„ç”Ÿç‰©å­¦è¿‡ç¨‹ï¼Œå¹¶é€‰æ‹©åˆé€‚çš„æœºå™¨å­¦ä¹ æ¨¡åž‹æ¥å®Œæˆæ¯ä¸ªä»»åŠ¡ã€‚å…·ä½“çš„æ¨¡åž‹é€‰æ‹©å’Œå‚æ•°è®¾ç½®éœ€è¦æ ¹æ®å®žéªŒç»“æžœè¿›è¡Œè°ƒæ•´å’Œä¼˜åŒ–ã€‚æŸå¤±å‡½æ•°çš„è®¾è®¡éœ€è¦èƒ½å¤Ÿåæ˜ é¢„æµ‹çš„å‡†ç¡®æ€§å’Œå¯é æ€§ã€‚

## ðŸ“Š å®žéªŒäº®ç‚¹

è®ºæ–‡æž„å»ºäº†ä¸€ä¸ªé«˜è´¨é‡çš„MHC-IIæ•°æ®é›†ï¼Œå¹¶åœ¨æ­¤åŸºç¡€ä¸Šè¿›è¡Œäº†å¤šå°ºåº¦é¢„æµ‹ä»»åŠ¡çš„åŸºå‡†æµ‹è¯•ã€‚å®žéªŒç»“æžœè¡¨æ˜Žï¼Œè¯¥æ¡†æž¶èƒ½å¤Ÿæœ‰æ•ˆåœ°æé«˜MHC-IIæŠ—åŽŸè¡¨ä½é¢„æµ‹çš„å‡†ç¡®æ€§ã€‚å…·ä½“æ€§èƒ½æ•°æ®å’Œå¯¹æ¯”åŸºçº¿æœªåœ¨æ‘˜è¦ä¸­æ˜Žç¡®ç»™å‡ºï¼Œä½†å¼ºè°ƒäº†è¯¥æ¡†æž¶ä¸ºæœªæ¥ç ”ç©¶å¥ å®šäº†åŸºç¡€ã€‚

## ðŸŽ¯ åº”ç”¨åœºæ™¯

è¯¥ç ”ç©¶æˆæžœå¯åº”ç”¨äºŽå…ç–«æ²»ç–—é¢†åŸŸï¼ŒåŠ é€ŸMHC-IIæŠ—åŽŸè¡¨ä½çš„å‘çŽ°ï¼Œä»Žè€Œä¿ƒè¿›æ–°åž‹ç–«è‹—å’Œå…ç–«ç–—æ³•çš„å¼€å‘ã€‚é€šè¿‡é¢„æµ‹å“ªäº›æŠ—åŽŸèƒ½å¤Ÿè¢«MHC-IIåˆ†å­å‘ˆé€’ï¼Œç ”ç©¶äººå‘˜å¯ä»¥æ›´æœ‰æ•ˆåœ°è®¾è®¡é’ˆå¯¹ç‰¹å®šç–¾ç—…çš„å…ç–«æ²»ç–—æ–¹æ¡ˆï¼Œä¾‹å¦‚ç™Œç—‡å’Œè‡ªèº«å…ç–«æ€§ç–¾ç—…ã€‚æ­¤å¤–ï¼Œè¯¥ç ”ç©¶è¿˜å¯ä»¥ä¸ºä¸ªæ€§åŒ–å…ç–«æ²»ç–—æä¾›æ”¯æŒï¼Œæ ¹æ®æ‚£è€…çš„MHC-IIåŸºå› åž‹ï¼Œé¢„æµ‹æœ€æœ‰æ•ˆçš„æŠ—åŽŸè¡¨ä½ã€‚

## ðŸ“„ æ‘˜è¦ï¼ˆåŽŸæ–‡ï¼‰

> Antigenic epitope presented by major histocompatibility complex II (MHC-II) proteins plays an essential role in immunotherapy. However, compared to the more widely studied MHC-I in computational immunotherapy, the study of MHC-II antigenic epitope poses significantly more challenges due to its complex binding specificity and ambiguous motif patterns. Consequently, existing datasets for MHC-II interactions are smaller and less standardized than those available for MHC-I. To address these challenges, we present a well-curated dataset derived from the Immune Epitope Database (IEDB) and other public sources. It not only extends and standardizes existing peptide-MHC-II datasets, but also introduces a novel antigen-MHC-II dataset with richer biological context. Leveraging this dataset, we formulate three major machine learning (ML) tasks of peptide binding, peptide presentation, and antigen presentation, which progressively capture the broader biological processes within the MHC-II antigen presentation pathway. We further employ a multi-scale evaluation framework to benchmark existing models, along with a comprehensive analysis over various modeling designs to this problem with a modular framework. Overall, this work serves as a valuable resource for advancing computational immunotherapy, providing a foundation for future research in ML guided epitope discovery and predictive modeling of immune responses.

